A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Amgen
- 21 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2018 Planned End Date changed from 30 Nov 2018 to 23 Jan 2019.
- 26 Oct 2018 Planned primary completion date changed from 30 Nov 2018 to 23 Jan 2019.